Vaccines Market By Technology Type (Recombinant and Conjugate Vaccines, Live Attenuated Vaccines, Inactivated Vaccines, Toxoid Vaccines, Others), By Indication (Pneumococcal Disease, Influenza, Human Papilloma Virus, Meningococcal Disease, Rotavirus, Vari

Vaccines Market By Technology Type (Recombinant and Conjugate Vaccines, Live Attenuated Vaccines, Inactivated Vaccines, Toxoid Vaccines, Others), By Indication (Pneumococcal Disease, Influenza, Human Papilloma Virus, Meningococcal Disease, Rotavirus, Varicella, Measles, Mumps, and Rubella, Diphtheria, Pertussis, and Tetanus (DTP), Polio, Hepatitis, Other Indications), By End User (Pediatric, Adults, Travelers): Global Opportunity Analysis and Industry Forecast, 2024-2035

The vaccine market was valued at $43.2 billion in 2023 and is projected to reach $90.7 billion by 2035, registering a CAGR of 6.4% from 2024 to 2035. A vaccine is a biological preparation that provides immunity to a particular infectious disease. It typically contains weakened or inactive forms of the pathogen, its toxins, or surface proteins, which stimulate the immune system to recognize and remember the pathogen. When people are vaccinated, their immune system responds by producing antibodies and activating immune cells specific to that pathogen. This creates a defense mechanism within the body, so if a person is later exposed to the actual infectious agent, the immune system can quickly recognize and destroy it, preventing or reducing the severity of the disease. Vaccines have been instrumental in controlling and eradicating many deadly diseases throughout history, making them one of the most significant advancements in modern medicine.
The growth of the vaccine market is primarily driven by rise in prevalence of diseases, such as influenza, pneumococcal disease, HPV, and other infections, requiring administration of vaccines. For instance, in 2023, Centers for Disease Control and Prevention (CDC) estimated that 31 million people were sick with flu. In addition, government investment in vaccine research and development, manufacturing infrastructure, and public immunization programs significantly impacts the vaccine market. Public-private partnerships, grants, tax incentives, and regulatory frameworks incentivize vaccine development and ensure safety, efficacy, and quality standards. Regulatory agencies, such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the World Health Organization (WHO), play pivotal roles in evaluating and approving vaccines for licensure, which influences market access and adoption. However, the high development costs, complex manufacturing processes, and stringent regulatory requirements contribute to the high prices of vaccines, limiting affordability, especially in low- and middle-income countries (LMICs) which may restrain the market growth. In contrast, due to ongoing advancements in biotechnology, genomics, and immunology, there is an opportunity to expand disease prevention and control through the development of new and improved vaccines. Emerging infectious diseases, antimicrobial resistance, and re-emerging pathogens underscore the need for innovative vaccine solutions to address unmet medical needs and mitigate public health threats. The vaccine market is segmented on the basis of technology type, indication, end user, and region. By technology type, the market is categorized into recombinant and conjugate vaccines, live attenuated vaccines, inactivated vaccines, toxoid vaccines, and others. As per indication, the market is divided into pneumococcal disease, influenza, human papilloma virus, meningococcal disease, rotavirus, varicella, measles, mumps, and rubella, diphtheria, pertussis, and tetanus (DTP), polio, hepatitis, and other indications. Depending on end user, the market is categorized into pediatric, adults, and travelers. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA). Major key players that operate in the global vaccine market are Merck & Co., Inc., Pfizer, Sanofi, Serum Institute of India Pvt. Ltd., Bavarian Nordic, CSL Limited, Emergent Bio Solutions Inc., GlaxoSmithKline plc., Zhi Fei Biological, and Bharat Biotech. The key players operating in the market have adopted clinical trial, product launch, product approval, and expansion as their key strategies to expand their product portfolio.

Key Benefits for Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the vaccines market analysis from 2023 to 2035 to identify the prevailing vaccines market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the vaccines market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global vaccines market trends, key players, market segments, application areas, and market growth strategies. Additional benefits you will get with this purchase are:
Regulatory Guidelines
Historic market data
Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Technology Type

Inactivated Vaccines
Toxoid Vaccines
Others
Recombinant and Conjugate Vaccines
Live Attenuated Vaccines

By Indication

Pneumococcal Disease
Influenza
Human Papilloma Virus
Meningococcal Disease
Rotavirus
Varicella
Measles, Mumps, and Rubella
Diphtheria, Pertussis, and Tetanus (DTP)
Polio
Hepatitis
Other Indications

By End User

Pediatric
Adults
Travelers

By Region

North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
India
Australia
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
Key Market Players
CSL Limited
Emergent Bi
Solutions Inc.
GlaxoSmithKline Plc.
Merck & Co., Inc.
Pfizer
Sanofi
Serum Institute of India Pvt. Ltd.
Bavarian Nordic
Zhi Fei Biological
Bharat Biotech